

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

**STA Ruxolitinib for treating polycythaemia vera (review of
TA356)**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No equality issues were raised during the scoping process.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No other equality issues have been identified.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No other equality issues have been identified.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?

See section 3.20 of the draft guidance document.

Approved by Associate Director (name): ...Linda Landells.....

Date: 25 May 2023

Final draft guidance

(when draft guidance issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

There were concerns raised that polycythaemia vera is a rare disease and it is therefore challenging to conduct large clinical trials. This contributes to uncertainty in the results. The committee noted that disease rarity is not an equality issue. However, the committee take these factors, such as evidence generation, into account when making decisions.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No.

5. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

See section 3.21 of the final draft guidance document.

Approved by Associate Director (name): Jasdeep Hayre

Date: 1 August 2023